The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.
Indian J Ophthalmol
;
2007 Nov-Dec; 55(6): 445-50
Artigo
em Inglês
| IMSEAR
| ID: sea-70838
ABSTRACT
In the last few years anti-vascular endothelial growth factor (VEGF) therapy has changed the paradigm in the treatment of neovascular age-related macular degeneration (ARMD). Besides, its potential use in the treatment of diabetic retinopathy and other possible proliferative vascular disorders has also shown promise. Clinical trial results have shown tremendous beneficial effect of ranibizumab in ARMD. Off-label use of bevacizumab has also shown similar benefit but long-term and clinical trial results do not exist. Some of the potential questions in the use of anti-VEGF are recurring cost, possible long-term effect on physiological function of VEGF and determination of endpoint of treatment. Overall, the use of anti-VEGF therapy in ocular angiogenesis has proven to be beneficial at least now.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Humanos
/
Ensaios Clínicos como Assunto
/
Inibidores da Angiogênese
/
Fator A de Crescimento do Endotélio Vascular
/
Degeneração Macular
Idioma:
Inglês
Revista:
Indian J Ophthalmol
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS